- Home
- SAVA vs PFO Comparison
SAVA vs PFO Comparison
Compare SAVA & PFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- PFO
- Stock Information
- Founded
- SAVA 1998
- PFO 1991
- Country
- SAVA United States
- PFO United States
- Employees
- SAVA N/A
- PFO N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- PFO Finance Companies
- Sector
- SAVA Health Care
- PFO Finance
- Exchange
- SAVA Nasdaq
- PFO Nasdaq
- Market Cap
- SAVA 102.4M
- PFO 121.4M
- IPO Year
- SAVA N/A
- PFO N/A
- Fundamental
- Price
- SAVA $2.16
- PFO $9.43
- Analyst Decision
- SAVA Hold
- PFO
- Analyst Count
- SAVA 1
- PFO 0
- Target Price
- SAVA $2.00
- PFO N/A
- AVG Volume (30 Days)
- SAVA 607.2K
- PFO 31.8K
- Earning Date
- SAVA 11-06-2025
- PFO 01-01-0001
- Dividend Yield
- SAVA N/A
- PFO 6.51%
- EPS Growth
- SAVA N/A
- PFO N/A
- EPS
- SAVA N/A
- PFO N/A
- Revenue
- SAVA N/A
- PFO N/A
- Revenue This Year
- SAVA N/A
- PFO N/A
- Revenue Next Year
- SAVA N/A
- PFO N/A
- P/E Ratio
- SAVA N/A
- PFO N/A
- Revenue Growth
- SAVA N/A
- PFO N/A
- 52 Week Low
- SAVA $1.15
- PFO $6.90
- 52 Week High
- SAVA $33.98
- PFO $8.51
- Technical
- Relative Strength Index (RSI)
- SAVA 45.76
- PFO 71.21
- Support Level
- SAVA $2.12
- PFO $9.27
- Resistance Level
- SAVA $2.40
- PFO $9.31
- Average True Range (ATR)
- SAVA 0.10
- PFO 0.05
- MACD
- SAVA -0.01
- PFO 0.01
- Stochastic Oscillator
- SAVA 17.24
- PFO 98.08
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.